BrightPath Biotherapeutics Co., Ltd.

4594

JP3274140007

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 03:00:37 17/07/2024 BST			5-day change	1st Jan Change
67 ^JPY	+4.69%		+3.12%	-24.14%

07-05	BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥2.67 million in funding	CI
06-19	BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥2.67 million in funding	CI

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥2.67 million in funding

July 04, 2024

On July 5, 2024, BrightPath Biotherapeutics Co., Ltd. closed the transaction.

Latest news about BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥2.67 million in funding	07-04	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥2.67 million in funding	06-18	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	11-29	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	11-13	CI
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index	19/09/22	CI
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine	14/04/22	MT
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment	14/04/22	MT
Brightpath Biotherapeutics Announces Preclinical Data on BP1209	13/04/22	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	31/01/22	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	13/01/22	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	22/04/20	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	06/04/20	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	09/11/18	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018	10/08/18	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	11/05/18	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	14/02/18	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm	07/12/17	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥12.17 million in funding from Credit Suisse Securities Limited, Investment Arm	21/11/17	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	10/11/17	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	14/08/17	CI
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo	23/07/17	CI
GreenPeptide Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	12/05/17	CI
GreenPeptide Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2016, Provides Earnings Guidance for the Year Ending March 31, 2017	10/02/17	CI
GreenPeptide Co., Ltd. Announces Notice of Initiation of Phase II Clinical Trial of GRN-1201	27/01/17	CI
Advanced Immunotherapy Co., Ltd. announced that it has received funding from GreenPeptide Co., Ltd.	30/11/16	CI

Chart BrightPath Biotherapeutics Co., Ltd.

Duration

Period

Chart BrightPath Biotherapeutics Co., Ltd.

More charts

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q1 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRIGHTPATH BIOTHERAPEUTICS CO., LTD.	-24.14%	32.19M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research